Contrasting Beta Bionics (BBNX) & Its Rivals

Beta Bionics (NASDAQ:BBNX) is one of 142 publicly-traded companies in the “MED INSTRUMENTS” industry, but how does it weigh in compared to its peers? We will compare Beta Bionics to related companies based on the strength of its risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Beta Bionics and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Beta Bionics	$65.12 million	-$54.76 million	-6.63
Beta Bionics Competitors	$1.75 billion	$196.07 million	5.41

Beta Bionics’ peers have higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

54.1% of shares of all “MED INSTRUMENTS” companies are held by institutional investors. 14.0% of shares of all “MED INSTRUMENTS” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Beta Bionics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1	3	8	1	2.69
Beta Bionics Competitors	1222	3824	7155	271	2.52

Beta Bionics presently has a consensus price target of $28.22, indicating a potential downside of 2.58%. As a group, “MED INSTRUMENTS” companies have a potential upside of 15.10%. Given Beta Bionics’ peers higher probable upside, analysts plainly believe Beta Bionics has less favorable growth aspects than its peers.

Profitability

This table compares Beta Bionics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-87.89%	-35.72%	-20.69%
Beta Bionics Competitors	-482.31%	-268.83%	-21.33%

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.